Triple Negative Breast Cancer (TNBC) Research Grant

Background & Purpose:
Triple Negative Breast Cancer (TNBC) – defined as estrogen receptor, progesterone receptor and human epidermal growth factor receptor type 2 (HER2) negativity – is heterogeneous with respect to biology, prognosis and response to treatment. TNBC can be associated with BRCA1 & BRCA2 mutations and is associated with younger age at diagnosis and with poorer outcomes compared with non-TNBC. Studies are needed to improve our understanding of its biology and current management and outcome of patients diagnosed with TNBC.

This funding opportunity has been made available through generous philanthropic support to the UF Health Cancer Center. It recognizes that i) the study of TNBC is underrepresented in academic and industry research portfolios, and ii) there exists a great need to advance our understanding of the genetics and biology of TNBC and for implementing new strategies for clinical trials.

The goals of the TNBC Research Grant are to:
- Identify new research opportunities focused on the biology or treatment of TNBC;
- Create synergies and collaborations among UF Health Cancer Center members and other members of University of Florida, Gainesville;
- Stimulate applications for future program-type federal or national extramural funding.

Eligibility:
Grant applications will be comprised of an individual research project led by a Principal Investigator or Co-Principal Investigators. Principal Investigators must be cancer center members and full-time faculty. Applications that involve collaborations between lab scientists and clinical investigators are desirable, but not mandatory.

Grant applications will provide a scientific rationale, project narrative, significance, detailed timeline and budget. The minimal requirements for the grant applications are:
- A project narrative that explicitly focuses on the genetics, biology, prevention or treatment of TNBC, recognizing that TNBC is a unique subtype of breast cancer.
- A project narrative that explicitly presents the goals and significance, as well as future potential growth of the overall project.

Award Amount and Duration:
- The maximum award amount is $50,000 per award. Proposals with lower budgets will be considered. IDCs are not allowed. PI & key personnel/co-investigator salary support is not allowed. Funds may be used for support personnel, supplies, core services, and other expenses.
- The award period is 12 months, with the expectation that all funds will be expended within that term.
- The award period is 24 months for clinical research projects requiring IRB approval, with the expectation that all funds will be expended within that term.
- Up to two proposals will be funded, depending on the quality of science and availability of funds. Funds are expected to be released by December 2018.

The deadline for receipt of applications is: October 8, 2018. Applications should be submitted to: Research Administration: reseachadmin@cancer.ufl.edu
REQUIRED GRANT APPLICATION COMPONENTS

A complete grant application package **must** contain all the required items listed in the Table below.

<table>
<thead>
<tr>
<th>Section</th>
<th>Category</th>
<th>Page Limit</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>General Project Information</td>
<td>1</td>
<td>Required. Identifies general project information, including the Principal Investigator(s), all key personnel, departmental and college affiliations, and project title.</td>
</tr>
<tr>
<td>B</td>
<td>Scientific Abstract</td>
<td>Max 30 lines</td>
<td>Required. This is the scientific description of the project.</td>
</tr>
<tr>
<td>C</td>
<td>Lay Abstract</td>
<td>Max 30 lines</td>
<td>Required. Please provide a lay summary of the project.</td>
</tr>
<tr>
<td>D</td>
<td>Long-term Vision</td>
<td>1</td>
<td>Required. Future plans to leverage research results into Externally Peer-Reviewed projects (NIH/NCI funding. Be specific in terms of funding announcement that the research team plans to pursue).</td>
</tr>
<tr>
<td>E</td>
<td>Project Narrative:</td>
<td>3</td>
<td>Required.</td>
</tr>
<tr>
<td></td>
<td>• Specific Aims (1 page)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Research Plan (2 pages):</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>o Significance</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>o Innovation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>o Approach</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>Literature Cited</td>
<td>No limit</td>
<td>Required. The budget must explain the planned spending for each Principal Investigator (if applicable). <strong>Please see below for allowable costs.</strong></td>
</tr>
<tr>
<td>G</td>
<td>Budget &amp; Budget Justification</td>
<td></td>
<td>Required for all key personnel. NIH format.</td>
</tr>
<tr>
<td>H</td>
<td>Biographical Sketches</td>
<td>5 per person</td>
<td>Required for all key personnel. NIH format.</td>
</tr>
<tr>
<td>I</td>
<td>Other Support</td>
<td></td>
<td>Required. NIH format. All other active and pending awards for the Principal Investigators.</td>
</tr>
</tbody>
</table>

**Allowable Costs include the following:**
- Technical or laboratory staff salaries (including fringe benefits)
- Research/laboratory supplies
- Shared Resource expenses
- Stipends (including fringe benefits)
- Animal costs
- Patient care costs and stipends
- Research related contractual agreements
- Software (prior approval required)
Review Criteria:

Applications will be evaluated on:
- Significance, methodological approach, scientific merit and innovation;
- How the science will ultimately translate to patient care;
- Potential for identifying risk factors, developing prevention strategies, improving treatment outcomes or survivorship;
- Relevance to the cancer center’s mission and goals;
- Potential to result in peer-reviewed extramural funding;
- Budget and timeline appropriateness.

Awardee Requirements:
- Grantees must submit a progress report 3 months before the end of project.
- Grantees will be required to present, in report form and/or presentation form, on use of the funding and next steps to advance their research.